TEM — Tempus AI, Inc.
$67.61+5.96%
Last close: · regular session
Pre-market $67.36 -0.38% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for TEM in the TickerWise workspace.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Company profile
- Sector: Healthcare
- Industry: Medical - Healthcare Information Services
- Country: US
- Exchange: NASDAQ
- Employees: 2,400
- Website: https://www.tempus.com
Latest SEC filings for TEM
Latest TEM news
- Here's How Tempus AI Demonstrates Improving Operating Leverage Read article
- Tempus AI Expands Strategic Collaborations to Drive Future Growth Read article
- Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? Read article
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure Read article
- Tempus AI expands cancer therapy deal with Moderna, Merck Read article
- Tempus Announces Multi-Year Collaboration with Moderna and Merck Read article
- Here's How Tempus AI is Capitalizing on AI-ECG Market Growth Read article
- Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.